Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 68.2 kDa. The protein migrates as 80-110 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human TrkA (33-417), Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human Beta-NGF Protein, premium grade (Cat. No. BEF-H5214) at 1 μg/mL (100 μL/well) can bind Human TrkA (33-417), Mouse IgG2a Fc Tag (Cat. No. TRA-H5259) with a linear range of 0.1-16 ng/mL (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Entrectinib | NMS-E628; RXDX-101; RG-6268 | Approved | Nerviano Medical Sciences Srl | Rozlytrek, 罗圣全 | Japan | Carcinoma, Non-Small-Cell Lung | Chugai Pharmaceutical Co Ltd | 2019-06-18 | Breast Neoplasms; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Hepatic Insufficiency; Lymphoproliferative Disorders; Colorectal Neoplasms; Sarcoma; Brain Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Neuroendocrine Tumors; Central Nervous System Neoplasms; Neoplasms; Salivary Gland Neoplasms; Pancreatic Neoplasms; Carcinoma, Renal Cell; Hematologic Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma | Details |
Larotrectinib sulfate | LOXO-101; ARRY-470; BAY-2757556 | Approved | Array Biopharma | Vitrakvi, 维泰凯 | United States | Solid tumours | Bayer Healthcare Pharmaceuticals Inc | 2018-11-26 | Glioma; Multiple Myeloma; Urinary Bladder Neoplasms; Histiocytosis, Langerhans-Cell; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Histiocytic Sarcoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Thyroid Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Lung Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Melanoma; Uterine Cervical Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Ependymoma; Fibrosarcoma; Rhabdomyosarcoma; Medulloblastoma; Leukemia; Ovarian Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Hematologic Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Neoplasms; Wilms Tumor; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Colonic Neoplasms | Details |
Repotrectinib | BMS-986472; ZL-2308; TPX-0005 | Approved | Turning Point Therapeutics Inc | 奥凯乐, Augtyro | United States | Carcinoma, Non-Small-Cell Lung | Bristol-Myers Squibb Company | 2023-11-15 | Solid tumours; Neoplasms; Central Nervous System Neoplasms; Hepatic Insufficiency; Lymphoma; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Tavilermide | MIM-D3; NMG938VJ6T (UNII code) | Phase 3 Clinical | Mimetogen Pharmaceuticals | Keratoconjunctivitis Sicca; Dry Eye Syndromes | Details |
Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Leukemia; Leukemia, Myeloid; Bone Marrow Neoplasms; Polycythemia Vera; Prostatic Neoplasms; Neuroblastoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psoriasis; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
VC-004 | VC004; VC-004; VC 004 | Phase 3 Clinical | Jiangsu Vcare Pharmatech Co Ltd | Solid tumours; Cancer Pain; Pruritus; Dermatitis | Details |
SNA-125 | CT-340; SNA-125 | Phase 2 Clinical | Sienna Biopharmaceuticals Inc, Creabilis Sa | Pruritus; Psoriasis; Dermatitis, Atopic | Details |
Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Solid tumours; Skin Melanoma; Bone metastases; Pancreatic Neoplasms; Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Milciclib maleate | PHA-848125; TZLS-201; PHA-848125C; PHA-125; PHA-848125AC | Phase 2 Clinical | Tiziana Life Sciences Plc, Nerviano Medical Sciences Srl | Solid tumours; Thymoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
FCN-011 | FCN-011 | Phase 2 Clinical | Fochon Pharmaceuticals Ltd | Solid tumours | Details |
AK-1830 | AK-1830; ARRY-954 | Phase 2 Clinical | Array Biopharma | Low Back Pain | Details |
XZP-5955 | XZP-5955 | Phase 2 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
BEN-2293 | BEN-00002293; BEN-2293 | Phase 2 Clinical | Benevolentai Bio Ltd | Dermatitis, Atopic | Details |
TQB-3558 | TQB-3558; CT-3417 | Phase 1 Clinical | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Solid tumours | Details |
BPI-28592 | BPI-28592 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
ACD-856 | ACD-856 | Phase 1 Clinical | Alzecure Pharma Ab | Alzheimer Disease; Cognition Disorders | Details |
HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
STSP-0902 | STSP-0902; STSP0902 | Phase 1 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Keratitis; Oligospermia; Asthenozoospermia | Details |
BR-01T | BR01T; BR-01T | Phase 1 Clinical | Xiyuan Anjian Pharmaceutical (Shanghai) Co Ltd | Low Back Pain | Details |
ND-003 (NewDEL Biotech) | ND003 (NewDEL Biotech); ND-003 (NewDEL Biotech) | Phase 1 Clinical | Shenzhen NewDEL Biotech Co Ltd | Solid tumours; Idiopathic Pulmonary Fibrosis; Neoplasms; Renal fibrosis; Pulmonary Fibrosis; Gastrointestinal Stromal Tumors; Renal Insufficiency, Chronic; Dermatitis, Atopic | Details |
HT006.2.2 | HT006.2.2; HT-006.2.2 | Phase 1 Clinical | Wuhan Hiteck Biological Pharma Co Ltd | Keratitis | Details |
JND-5932 | JND-5932; JND5932 | Phase 1 Clinical | Jinan University | Neoplasms | Details |
PBI-200 | PBI-200 | Phase 1 Clinical | Pyramid Biosciences | Solid tumours; Desmoplastic Small Round Cell Tumor; Brain Neoplasms | Details |
FCN-098 | FCN-098; FCN098 | Phase 1 Clinical | Fochon Pharmaceuticals Ltd, Fochon Pharmaceuticals Ltd | Solid tumours; Neoplasms | Details |
E-2511 | E2511; E-2511 | Phase 1 Clinical | Eisai Inc | Details | |
VMD-928 | VMD-928 | Phase 1 Clinical | Vm Oncology Llc | Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Uterine Neoplasms; Lung Neoplasms; Appendiceal Neoplasms; Thymoma; Sarcoma; Breast Neoplasms; Ovarian Neoplasms; Carcinoma, Adenoid Cystic; Mesothelioma; Pancreatic Neoplasms; Esophageal Neoplasms; Esthesioneuroblastoma, Olfactory; Solid tumours; Head and Neck Neoplasms | Details |
This web search service is supported by Google Inc.